Phase III study of adjuvant ado-trastuzumab emtansine vs. trastuzumab for residual invasive Her2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis. SABCS - Loibl, S; Mano, MS; Untch, M (2023)